Care Home Communication

This document outlines key areas to share with your loved one’s care home staff. Please note, the information below is based on personal struggles/challenges with care homes experienced by my […]
uniQure Provides Regulatory Update

Dear Huntington’s Disease Community, We are writing to share an update following our recent Type A meeting with the U.S. Food and Drug Administration (FDA.) On March 2, 2026, uniQure […]
Harness Therapeutics Nominates HRN001 Drug Candidate for HD and Launches Clinical Advisory Board

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board Cambridge, UK, 16 February 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable […]
Still Here: Redefining a Meaningful Life With Huntington’s Disease

There is a question I’ve been asked in many forms since my diagnosis: How do you live a meaningful life with Huntington’s disease? Sometimes it’s asked gently, sometimes with curiosity, […]
Novartis Announces INVEST-HD

Novartis development of Votoplam in HD: INVEST-HD Phase 3 trial information now available February 3rd 2026 Dear Huntington’s disease Community, We are delighted to share an update on the development […]
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease

The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 4, 2026– Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader […]
An Update on SKY-0515

Dear friends in the Huntington’s disease community, We’d like to share an update on ongoing research into SKY-0515, an investigational medicine being studied for Huntington’s disease (HD). A scientific press […]
What My Diagnosis Taught Me About Slowing Down With Purpose

Before Huntington’s disease entered my life, I moved through the world at a pace that made sense for the life I thought I was building. I held onto the idea […]
uniQure Announces Meeting with FDA

January 9, 2026 7:05 AM EST uniQure Announces Type A Meeting Scheduled with FDA LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading […]
An Update from LoQus23

LoQus23 Therapeutics is a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myotonic dystrophy type […]